Carl Byrnes

Aratana Therapeutics Inc (NASDAQ: PETX) seems to be firing on all cylinders and the recent weakness in shares represents an attractive buying opportunity, Lake Street Capital Markets’ Carl Byrnes said in a report. He reiterated a Buy rating on the company, with a price target of $15....